{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:21Z","timestamp":1792782621770,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","id":[{"id":"https:\/\/ror.org\/00q1fsf04","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Kollagenosen wie systemischer Lupus erythematodes (SLE) und systemische Sklerose (SSc) erfordern aufgrund multisystemischer Manifestationen eine interdisziplin\u00e4re Versorgung. Insbesondere die pulmonale Beteiligung (CTD-ILD) ist prognostisch relevant. Daten zur realen Versorgungssituation sind jedoch limitiert, wodurch strukturelle Defizite schwer identifizierbar bleiben.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>Mit einem selbstentwickelten 14-moduligen Fragebogen wurden zwischen 09\/2024 und 03\/2025 insgesamt 2173 Praxen verschiedener Fachrichtungen in Rheinland-Pfalz und dem Saarland kontaktiert. Erfasst wurden Versorgungsstrukturen, Patientenzahlen, pulmonale Manifestationen sowie pharmakologische Therapien. Die Auswertung erfolgte deskriptiv auf Behandler-Ebene.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Insgesamt 67\u00a0Einrichtungen berichteten \u00fcber 1569 Patienten (SLE:\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u2009859; SSc:\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u2009421), von denen 286 (\u224818\u202f%) eine Lungenbeteiligung aufwiesen. Die Versorgung erfolgt \u00fcberwiegend in spezialisierten Zentren, jedoch mit relevanter Beteiligung des niedergelassenen Bereichs. Es zeigten sich deutliche Unterschiede in der Therapie: W\u00e4hrend im ambulanten Sektor h\u00e4ufiger Glukokortikoide in h\u00f6heren Dosierungen eingesetzt werden (bis \u224828\u202f% &gt;\u202f10\u202fmg\/d), gelingt in Zentren durch vermehrten Einsatz von Biologika und krankheitsmodifizierenden Therapien, insbesondere Mycophenolat-Mofetil (MMF), eine signifikante Reduktion der Glukokortikoiddosis (\u22481,5\u202f% &gt;\u202f10\u202fmg\/d). MMF wird dabei vor allem in der rheumatologischen Versorgung deutlich h\u00e4ufiger eingesetzt als in anderen Fachrichtungen. Insgesamt bestehen Unterschiede im Einsatz leitliniengerechter Basistherapien sowie in der Symptomwahrnehmung.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die Ergebnisse zeigen relevante Versorgungsdefizite mit \u00dcbergewicht der Glukokortikoidtherapie und unzureichender Nutzung evidenzbasierter DMARDs wie MMF im niedergelassenen Bereich. Ursachen sind begrenzte rheumatologische Expertise, eingeschr\u00e4nkter Zugang zu spezialisierten Therapien und mangelnde interdisziplin\u00e4re Vernetzung. Eine Verbesserung erfordert den Ausbau rheumatologischer Strukturen, fr\u00fchzeitige fach\u00e4rztliche Anbindung sowie eine st\u00e4rkere Implementierung leitliniengerechter, steroidsparender Therapiestrategien.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-026-01830-4","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:37:20Z","timestamp":1781015840000},"page":"608-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Umfrage zur Versorgungssituation von Patient:innen mit systemischem Lupus erythematodes und systemischer Sklerose mit Lungenbeteiligung in Rheinland-Pfalz und dem Saarland","Survey of care situation for patients with systemic lupus erythematosus and systemic sclerosis with pulmonary involvement in Rhineland\u2013Palatinate and Saarland"],"prefix":"10.1007","volume":"85","author":[{"given":"Lennart","family":"Ha\u00dfdenteufel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Jahns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-598X","authenticated-orcid":false,"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-3780","authenticated-orcid":false,"given":"Matthias","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"9","key":"1830_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00393-022-01305-2","volume":"82","author":"K Albrecht","year":"2023","unstructured":"Albrecht\u00a0K, Binder\u00a0S, Minden\u00a0K, Poddubnyy\u00a0D, Regierer\u00a0AC, Strangfeld\u00a0A et\u00a0al (2023) Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. German version. Z\u00a0Rheumatol 82(9):727\u2013738. https:\/\/doi.org\/10.1007\/s00393-022-01305-2","journal-title":"Z Rheumatol"},{"issue":"9","key":"1830_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s00393-024-01491-1","volume":"83","author":"C Alberti","year":"2024","unstructured":"Alberti\u00a0C, Dreher\u00a0M, Triantafyllias\u00a0K, Schwarting\u00a0A (2024) Current patient care of systematic lupus erythematosus in Rhineland-Palatinate and Saarland. Z\u00a0Rheumatol 83(9):770\u2013777. https:\/\/doi.org\/10.1007\/s00393-024-01491-1","journal-title":"Z Rheumatol"},{"issue":"11","key":"1830_CR3","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1093\/rheumatology\/keaa127","volume":"59","author":"P Moinzadeh","year":"2020","unstructured":"Moinzadeh\u00a0P, Kuhr\u00a0K, Siegert\u00a0E, Mueller-Ladner\u00a0U, Riemekasten\u00a0G, G\u00fcnther\u00a0C et\u00a0al (2020) Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets. Rheumatology (Oxford) 59(11):3380\u20133389. https:\/\/doi.org\/10.1093\/rheumatology\/keaa127","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1830_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00393-019-0680-1","volume":"78","author":"K Albrecht","year":"2019","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Zink\u00a0A (2019) Long-term trends in rheumatology care. Zeitschrift f\u00fcr Rheumatologie 78(2):65\u201372. https:\/\/doi.org\/10.1007\/s00393-019-0680-1","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"issue":"7","key":"1830_CR5","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar\u00a0M, Rossides\u00a0M, Westerlind\u00a0H, Hesselstrand\u00a0R, Arkema\u00a0EV, Holmqvist\u00a0M (2021) Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) 60(7):3121\u20133133. https:\/\/doi.org\/10.1093\/rheumatology\/keab190","journal-title":"Rheumatology (Oxford)"},{"key":"1830_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0210-2022","author":"GM Joy","year":"2023","unstructured":"Joy\u00a0GM, Arbiv\u00a0OA, Wong\u00a0CK, Lok\u00a0SD, Adderley\u00a0NA, Dobosz\u00a0KM et\u00a0al (2023) Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev. https:\/\/doi.org\/10.1183\/16000617.0210-2022","journal-title":"Eur Respir Rev"},{"issue":"7","key":"1830_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00393-025-01675-3","volume":"84","author":"F Schumacher","year":"2025","unstructured":"Schumacher\u00a0F, Stanzel\u00a0SB, Zimmermann\u00a0M, Majorski\u00a0D, Wollsching-Strobel\u00a0M, Albrecht\u00a0K et\u00a0al (2025) H\u00e4ufigkeit interstitieller Lungenerkrankungen in der station\u00e4ren Rheumatologie. Zeitschrift f\u00fcr Rheumatologie 84(7):565\u2013571. https:\/\/doi.org\/10.1007\/s00393-025-01675-3","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"issue":"12","key":"1830_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos\u00a0GC, Lo\u00a0MS, Costa Reis\u00a0P, Sullivan\u00a0KE (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12(12):716\u2013730. https:\/\/doi.org\/10.1038\/nrrheum.2016.186","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1830_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa006","volume":"4","author":"M Sloan","year":"2020","unstructured":"Sloan\u00a0M, Harwood\u00a0R, Sutton\u00a0S, D\u2019Cruz\u00a0D, Howard\u00a0P, Wincup\u00a0C et\u00a0al (2020) Medically explained symptoms: a\u00a0mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol Adv Pract 4(1):rkaa006. https:\/\/doi.org\/10.1093\/rap\/rkaa006","journal-title":"Rheumatol Adv Pract"},{"key":"1830_CR10","volume-title":"Duale Reihe Innere Medizin","author":"A Keiwakus","year":"2018","unstructured":"Keiwakus\u00a0A, Bieber\u00a0C, Baenkler\u00a0HW (2018) Duale Reihe Innere Medizin. Georg Thieme Verlag KG, Stuttgart, New York"},{"issue":"25","key":"1830_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3238\/arztebl.2015.0423","volume":"112","author":"A Kuhn","year":"2015","unstructured":"Kuhn\u00a0A, Bonsmann\u00a0G, Anders\u00a0HJ, Herzer\u00a0P, Tenbrock\u00a0K, Schneider\u00a0M (2015) The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int 112(25):423\u2013432. https:\/\/doi.org\/10.3238\/arztebl.2015.0423","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"1830_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0961203310385552","volume":"20","author":"GM Daleboudt","year":"2011","unstructured":"Daleboudt\u00a0GM, Broadbent\u00a0E, Berger\u00a0SP, Kaptein\u00a0AA (2011) Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis. Lupus 20(3):290\u2013298. https:\/\/doi.org\/10.1177\/0961203310385552","journal-title":"Lupus"},{"issue":"Suppl 4(Suppl 4","key":"1830_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/ar3919","volume":"14","author":"A Lateef","year":"2012","unstructured":"Lateef\u00a0A, Petri\u00a0M (2012) Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 14(Suppl 4(Suppl 4)):S4. https:\/\/doi.org\/10.1186\/ar3919","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"1830_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1055\/a-2615-9127","volume":"150","author":"KM Jahns","year":"2025","unstructured":"Jahns\u00a0KM, Dreher\u00a0M, Triantafyllias\u00a0K, Hassdenteufel\u00a0L, Schwarting\u00a0A (2025) From renal crisis to lung fibrosis - systemic sclerosis in the course of time. Dtsch Med Wochenschr 150(16):975\u2013979. https:\/\/doi.org\/10.1055\/a-2615-9127","journal-title":"Dtsch Med Wochenschr"},{"issue":"10","key":"1830_CR15","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall\u00a0AJ, Bannert\u00a0B, Vonk\u00a0M, Air\u00f2\u00a0P, Cozzi\u00a0F, Carreira\u00a0PE et\u00a0al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809\u20131815. https:\/\/doi.org\/10.1136\/ard.2009.114264","journal-title":"Ann Rheum Dis"},{"issue":"10373","key":"1830_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann\u00a0ER, Andr\u00e9asson\u00a0K, Smith\u00a0V (2023) Systemic sclerosis. The Lancet 401(10373):304\u2013318. https:\/\/doi.org\/10.1016\/S0140-6736(22)01692-0","journal-title":"The Lancet"},{"issue":"7","key":"1830_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00393-008-0412-4","volume":"68","author":"R Fischer-Betz","year":"2009","unstructured":"Fischer-Betz\u00a0R, Schneider\u00a0M (2009) Antimalarials. A treatment option for every lupus patient!? Z\u00a0Rheumatol 68(7):584\u2013590. https:\/\/doi.org\/10.1007\/s00393-008-0412-4","journal-title":"Z Rheumatol"},{"issue":"6","key":"1830_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00393-019-0633-8","volume":"78","author":"J Mucke","year":"2019","unstructured":"Mucke\u00a0J, Fischer-Betz\u00a0R, Schneider\u00a0M (2019) State of the art: systemic lupus erythematosus. Z\u00a0Rheumatol 78(6):500\u2013510. https:\/\/doi.org\/10.1007\/s00393-019-0633-8","journal-title":"Z Rheumatol"},{"issue":"1","key":"1830_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Andersen\u00a0J, Aringer\u00a0M, Arnaud\u00a0L, Bae\u00a0SC et\u00a0al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases 83(1):15. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1830_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-025-01687-z","author":"J Mucke","year":"2025","unstructured":"Mucke\u00a0J, Anders\u00a0HJ, Aringer\u00a0M, Berlit\u00a0P, B\u00f6ltz\u00a0S, Burchardi\u00a0FC et\u00a0al (2025) Management of systemic lupus erythematosus-Including secondary antiphospholipid syndrome, fertility and pregnancy : S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Z\u00a0Rheumatol. https:\/\/doi.org\/10.1007\/s00393-025-01687-z","journal-title":"Z Rheumatol"},{"issue":"1","key":"1830_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","volume":"85","author":"A Fanouriakis","year":"2026","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Anders\u00a0HJ, Andersen\u00a0J, Aringer\u00a0M, Beresford\u00a0MW et\u00a0al (2026) EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis 85(1):75\u201390. https:\/\/doi.org\/10.1016\/j.ard.2025.09.007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1830_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo\u00a0F, Lescoat\u00a0A, Conaghan\u00a0PG, Bertoldo\u00a0E, \u010coli\u0107\u00a0J, Santiago\u00a0T et\u00a0al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340. https:\/\/doi.org\/10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1830_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/acr.25469","volume":"77","author":"D Mongin","year":"2025","unstructured":"Mongin\u00a0D, Matucci-Cerinic\u00a0M, Walker\u00a0UA, Distler\u00a0O, Becvar\u00a0R, Siegert\u00a0E et\u00a0al (2025) Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database. Arthritis Care Res (Hoboken) 77(5):649\u2013657. https:\/\/doi.org\/10.1002\/acr.25469","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3 Suppl 33","key":"1830_CR24","first-page":"S87","volume":"22","author":"K Takehara","year":"2004","unstructured":"Takehara\u00a0K (2004) Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 22(3 Suppl 33):S87\u2013S89","journal-title":"Clin Exp Rheumatol"},{"key":"1830_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-025-01695-z","author":"JC Henes","year":"2025","unstructured":"Henes\u00a0JC, Arndt\u00a0S, Berger\u00a0M, Czihal\u00a0M, Distler\u00a0J, Erbel\u00a0C et\u00a0al (2025) S2k-Leitlinie \u201eDiagnostik und Therapie der systemischen Sklerose\u201c. Zeitschrift f\u00fcr Rheumatologie. https:\/\/doi.org\/10.1007\/s00393-025-01695-z","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"issue":"9","key":"1830_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/s2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ, Furst\u00a0DE, Khanna\u00a0D, Kleerup\u00a0EC et\u00a0al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/s2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1830_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","volume":"25","author":"O Nadashkevich","year":"2006","unstructured":"Nadashkevich\u00a0O, Davis\u00a0P, Fritzler\u00a0M, Kovalenko\u00a0W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25(2):205\u2013212. https:\/\/doi.org\/10.1007\/s10067-005-1157-y","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1830_CR28","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/s2665-9913(22)00131-x","volume":"4","author":"S Ebata","year":"2022","unstructured":"Ebata\u00a0S, Yoshizaki\u00a0A, Oba\u00a0K, Kashiwabara\u00a0K, Ueda\u00a0K, Uemura\u00a0Y et\u00a0al (2022) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 4(8):e546\u2013e555. https:\/\/doi.org\/10.1016\/s2665-9913(22)00131-x","journal-title":"Lancet Rheumatol"},{"key":"1830_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002477","author":"S Kuster","year":"2022","unstructured":"Kuster\u00a0S, Jordan\u00a0S, Elhai\u00a0M, Held\u00a0U, Steigmiller\u00a0K, Bruni\u00a0C et\u00a0al (2022) Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002477","journal-title":"RMD Open"},{"issue":"10","key":"1830_CR30","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/s2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE, Goldin\u00a0J, Kim\u00a0G, Kuwana\u00a0M et\u00a0al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963\u2013974. https:\/\/doi.org\/10.1016\/s2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"issue":"10038","key":"1830_CR31","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/s0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna\u00a0D, Denton\u00a0CP, Jahreis\u00a0A, van Laar\u00a0JM, Frech\u00a0TM, Anderson\u00a0ME et\u00a0al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387(10038):2630\u20132640. https:\/\/doi.org\/10.1016\/s0140-6736(16)00232-4","journal-title":"Lancet"},{"issue":"1","key":"1830_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/s2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland\u00a0KB, Distler\u00a0O, Kuwana\u00a0M, Allanore\u00a0Y, Assassi\u00a0S, Azuma\u00a0A et\u00a0al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 9(1):96\u2013106. https:\/\/doi.org\/10.1016\/s2213-2600(20)30330-1","journal-title":"Lancet Respir Med"},{"issue":"26","key":"1830_CR33","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0K, Gahlemann\u00a0M, Azuma\u00a0A, Fischer\u00a0A, Mayes\u00a0M et\u00a0al (2019) Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease. New England Journal of Medicine 380(26):2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"1830_CR34","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41409-021-01355-1","volume":"56","author":"N Ait Abdallah","year":"2021","unstructured":"Ait Abdallah\u00a0N, Wang\u00a0M, Lansiaux\u00a0P, Puyade\u00a0M, Berthier\u00a0S, Terriou\u00a0L et\u00a0al (2021) Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. Bone Marrow Transplant 56(9):2259\u20132267. https:\/\/doi.org\/10.1038\/s41409-021-01355-1","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1830_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","volume":"78","author":"AE Miller","year":"2021","unstructured":"Miller\u00a0AE, Chitnis\u00a0T, Cohen\u00a0BA, Costello\u00a0K, Sicotte\u00a0NL, Stacom\u00a0R et\u00a0al (2021) Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. JAMA Neurol 78(2):241\u2013246. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4025","journal-title":"JAMA Neurol"},{"issue":"24","key":"1830_CR36","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar\u00a0JM, Farge\u00a0D, Sont\u00a0JK, Naraghi\u00a0K, Marjanovic\u00a0Z, Larghero\u00a0J et\u00a0al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. Jama 311(24):2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"Jama"},{"issue":"1","key":"1830_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM, Goldmuntz\u00a0EA, Keyes-Elstein\u00a0L, McSweeney\u00a0PA, Pinckney\u00a0A, Welch\u00a0B et\u00a0al (2018) Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N\u00a0Engl J Med 378(1):35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327","journal-title":"N Engl J Med"},{"issue":"10","key":"1830_CR38","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41584-025-01294-x","volume":"21","author":"JHW Distler","year":"2025","unstructured":"Distler\u00a0JHW, Kuwana\u00a0M, Assassi\u00a0S, Denton\u00a0CP (2025) Emerging therapies for the treatment of systemic sclerosis. Nat Rev Rheumatol 21(10):612\u2013625. https:\/\/doi.org\/10.1038\/s41584-025-01294-x","journal-title":"Nat Rev Rheumatol"},{"key":"1830_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.021","author":"KM Antoniou","year":"2025","unstructured":"Antoniou\u00a0KM, Distler\u00a0O, Gheorghiu\u00a0AM, Moor\u00a0CC, Vikse\u00a0J, Bizymi\u00a0N et\u00a0al (2025) ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG). Annals of the Rheumatic Diseases. https:\/\/doi.org\/10.1016\/j.ard.2025.08.021","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"13","key":"1830_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1177\/0961203314540352","volume":"23","author":"R Brinks","year":"2014","unstructured":"Brinks\u00a0R, Fischer-Betz\u00a0R, Sander\u00a0O, Richter\u00a0JG, Chehab\u00a0G, Schneider\u00a0M (2014) Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030. Lupus 23(13):1407\u20131411. https:\/\/doi.org\/10.1177\/0961203314540352","journal-title":"Lupus"},{"issue":"1","key":"1830_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40744-020-00195-7","volume":"7","author":"E Nyman","year":"2020","unstructured":"Nyman\u00a0E, Vaughan\u00a0T, Desta\u00a0B, Wang\u00a0X, Barut\u00a0V, Emmas\u00a0C (2020) Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study. Rheumatol Ther 7(1):201\u2013213. https:\/\/doi.org\/10.1007\/s40744-020-00195-7","journal-title":"Rheumatol Ther"},{"issue":"10","key":"1830_CR42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1136\/ard-2023-224514","volume":"83","author":"E Dures","year":"2024","unstructured":"Dures\u00a0E, Fariso\u011fullar\u0131\u00a0B, Santos\u00a0EJF, Molto\u00a0A, Feldthusen\u00a0C, Harris\u00a0C et\u00a0al (2024) 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 83(10):1260\u20131267. https:\/\/doi.org\/10.1136\/ard-2023-224514","journal-title":"Ann Rheum Dis"},{"key":"1830_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005267","author":"BG Kim","year":"2025","unstructured":"Kim\u00a0BG, Kim\u00a0J, Eun\u00a0Y, Park\u00a0DW, Kim\u00a0SH, Lee\u00a0H (2025) Comprehensive risk assessment for pulmonary manifestations in systemic lupus erythematosus: a\u00a0large-scale Korean population-based longitudinal study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2024-005267","journal-title":"RMD Open"},{"key":"1830_CR44","volume-title":"Kerndokumentation der regionalen kooperativen Rheumazentren - Versorgungstrends 2025","author":"K Thiele","year":"2025","unstructured":"Thiele\u00a0K, Albrecht\u00a0K, Alexander\u00a0T, Aringer\u00a0M, Detert\u00a0J, Eidner\u00a0T et\u00a0al (2025) Kerndokumentation der regionalen kooperativen Rheumazentren - Versorgungstrends 2025. Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin"},{"issue":"2","key":"1830_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00393-024-01539-2","volume":"83","author":"J Braun","year":"2024","unstructured":"Braun\u00a0J, Albrecht\u00a0K, Callhoff\u00a0J, Haase\u00a0I, Krause\u00a0A, Lakomek\u00a0HJ et\u00a0al (2024) Rheumatologische Versorgung in Deutschland. Zeitschrift f\u00fcr Rheumatologie 83(2):249\u2013284. https:\/\/doi.org\/10.1007\/s00393-024-01539-2","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"issue":"2","key":"1830_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/ard-2023-224205","volume":"83","author":"M Dreher","year":"2024","unstructured":"Dreher\u00a0M, Witte\u00a0T, Hoeper\u00a0K, Assmann\u00a0G, Proft\u00a0F, Poddubnyy\u00a0D et\u00a0al (2024) Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres. Ann Rheum Dis 83(2):184\u2013193. https:\/\/doi.org\/10.1136\/ard-2023-224205","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1830_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3200\/bmed.35.1.5-13","volume":"35","author":"S Danoff-Burg","year":"2009","unstructured":"Danoff-Burg\u00a0S, Friedberg\u00a0F (2009) Unmet needs of patients with systemic lupus erythematosus. Behav Med 35(1):5\u201313. https:\/\/doi.org\/10.3200\/bmed.35.1.5-13","journal-title":"Behav Med"},{"issue":"4","key":"1830_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00393-009-0522-7","volume":"69","author":"A Zink","year":"2010","unstructured":"Zink\u00a0A, Huscher\u00a0D, Schneider\u00a0M (2010) How closely does rheumatology treatment follow the guidelines?: ambition and reality. Z\u00a0Rheumatol 69(4):318\u2013326. https:\/\/doi.org\/10.1007\/s00393-009-0522-7","journal-title":"Z Rheumatol"},{"issue":"7","key":"1830_CR49","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14712598.2022.2096406","volume":"22","author":"\u00cd Rua-Figueroa Fern\u00e1ndez de Larrinoa","year":"2022","unstructured":"Rua-Figueroa Fern\u00e1ndez de Larrinoa \u00cd, Lozano\u00a0MJC, Fern\u00e1ndez-Cid\u00a0CM, Cobo Ib\u00e1\u00f1ez\u00a0T, Salman Monte\u00a0TC, Freire Gonz\u00e1lez\u00a0M et\u00a0al (2022) Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. Expert Opin Biol Ther 22(7):821\u2013829. https:\/\/doi.org\/10.1080\/14712598.2022.2096406","journal-title":"Expert Opin Biol Ther"},{"key":"1830_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005776","author":"C Sieiro Santos","year":"2025","unstructured":"Sieiro Santos\u00a0C, Del Galdo\u00a0F (2025) New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2025-005776","journal-title":"RMD Open"},{"issue":"1","key":"1830_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00393-020-00933-w","volume":"80","author":"M Aringer","year":"2021","unstructured":"Aringer\u00a0M, Baerwald\u00a0C, Bergner\u00a0R, Feuchtenberger\u00a0M, Gebhardt\u00a0C, Hagen\u00a0M et\u00a0al (2021) Rheumatologie im Medizinstudium. Zeitschrift f\u00fcr Rheumatologie 80(1):2\u20138. https:\/\/doi.org\/10.1007\/s00393-020-00933-w","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"1830_CR52","doi-asserted-by":"crossref","unstructured":"Strunz PP, Gernert M, Nagler LK, Labinsky H, Fr\u00f6hlich M, Stetter M, et\u00a0al. Survey on primary care for rheumatology patients in Lower Franconia and the contribution of digital health. Z Rheumatol. 2026;85(3):179\u201387. https:\/\/doi.org\/10.1007\/s00393-025-01754\u20115.","DOI":"10.1007\/s00393-025-01754-5"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01830-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01830-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01830-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:26:46Z","timestamp":1791458806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01830-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01830-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Schwarting ist PI der Datenerhebung und erhielt die F\u00f6rdersumme von Boehringer Ingelheim am Schwerpunkt Rheumatologie und klinische Immunologie der Universit\u00e4tsmedizin Mainz. Ziel der F\u00f6rderung des Projektes war die Sensibilisierung von Prim\u00e4rversorgern als Grundlage f\u00fcr den Aufbau einer spezialisierten Koordinationsstelle f\u00fcr die fr\u00fche diagnostische Abkl\u00e4rung und Therapie von Patienten mit Lungenbeteiligung bei Kollagenosen. Die pharmazeutische Firma hatte weder einen Einfluss auf die Datenerhebung oder -auswertung. Das Manuskript wurde der Firma zur Kenntnis vor Einreichung zugesandt. L.\u00a0Ha\u00dfdenteufel, K.\u00a0Jahns, C.\u00a0Alberti, A.\u00a0Schwarting und M.\u00a0Dreher geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}